Detalhe da pesquisa
1.
Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma.
Pharmacogenet Genomics
; 26(5): 243-7, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26928270
2.
SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin.
Front Pharmacol
; 13: 1042989, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36438828
3.
The role of pharmacogenetics in the treatment of osteosarcoma.
Drug Discov Today
; 21(11): 1775-1786, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27352631
4.
High-quality genotyping data from formalin-fixed, paraffin-embedded tissue on the drug metabolizing enzymes and transporters plus array.
J Mol Diagn
; 17(1): 4-9, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25528187
5.
A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment.
Clin Cancer Res
; 21(15): 3436-41, 2015 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25829401
6.
Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.
PLoS One
; 9(12): e115869, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25551397
7.
Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis.
Clin Sarcoma Res
; 2(1): 8, 2012 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-22587892